Celsion Corporation (NASDAQ:CLSN) today announced publication of the article, “Lyso-Thermosensitive Liposomal Doxorubicin for Treatment of Bladder Cancer,” in the International Journal of Hyperthermia
D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.